Tarsus Pharmaceuticals Investor Relations Material
Latest events
Q4 2023
Tarsus Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Tarsus Pharmaceuticals Inc
Access all reports
Tarsus Pharmaceuticals Inc. is a biopharmaceutical company primarily engaged in the development and commercialization of novel therapeutic candidates targeted at various ophthalmic conditions. Its leading product candidate, TP-03, is a novel therapy aimed at treating blepharitis caused by the infestation of Demodex mites and is also being developed to address meibomian gland disease. Furthermore, the company is working on TP-04 for the treatment of rosacea and TP-05, an oral tablet intended for the prevention of Lyme disease and community malaria reduction. Tarsus Pharmaceuticals Inc. is headquartered in Irvine, California, and its shares are listed on the Nasdaq.
Latest articles
Companies That Had Their IPO in 2019: Bull Market and Tech Dominance
Discussing the stock and IPO market in 2019, and the factors that led to the overall bullish performance of stocks during the year.
3 May 2024
Microsoft's Journey to Becoming the World's Most Valuable Company
Explore Microsoft's rise from a garage startup to the world's most valuable company, highlighting Bill Gates' role in shaping the digital revolution.
3 May 2024
Bill Gates: The Man Who Put a Computer in Every Home
Explore the life of Bill Gates, from co-founding Microsoft to global philanthropy, and his lasting impact on the world.
2 May 2024
Ticker symbol
Country
đșđž United States